Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 7,27 € (-1,62%). La mediana è 7,27 € (-1,62%).

Acquista
  16
Mantieni
  3
Vendi
  4

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Novavax stock falls after WHO assessment of plague risk

    The WHO rates the overall plague risk in Russia as low, prompting vaccine stocks such as Novavax, Moderna and BioNTech to record short-term price declines. Novavax fell sharply on the NASDAQ, and Moderna and BioNTech also slipped. Analysts view the moves as speculative reactions to headlines and emphasize that the companies' fundamentals have not materially changed; investors should approach short-term trading decisions with caution. » Altro su finanzen.net


  • Novavax expands business model: partnerships and Matrix‑M to secure financial runway into the 2030s

    At the Citigroup Biopharma Summit, Novavax announced a strategic shift from a pure COVID vaccine maker to a platform company centered on the adjuvant Matrix‑M. Near‑term drivers are partnerships with Sanofi (up to $200 million in milestones) and Pfizer (a $30 million upfront payment, milestone potential up to $500 million plus royalties). Sanofi has begun shipping NUVAXOVID in the U.S.; Novavax emphasizes gradual market share gains over multiple seasons. At the same time, the company is advancing Matrix‑M research in oncology and a C. difficile candidate, keeping R&D spending lean and viewing the partnerships as the basis for extended financial runway. » Altro su de.investing.com


  • Novavax makes strategic shift to licensing model with Matrix‑M

    Novavax is moving from direct commercialization to a technology-licensing platform and plans to license its saponin-based adjuvant Matrix‑M and nanoparticle protein technology to major pharma partners. The company received $800 million in upfront and milestone payments from Pfizer and Sanofi over the past three years, has identified additional near-term milestones of $200 million, and cut its cost base by 80–90%, extending its financial runway to more than two years. Novavax is targeting non-GAAP profitability in 2028 (requiring revenue > $150 million), sees significant potential for combined COVID‑flu vaccines and expanded oncology applications, and expects multiple upcoming catalysts from partner studies and proof-of-concept data. » Altro su de.investing.com


  • Novavax partners receive approvals for XFG-targeted COVID-19 vaccine

    Sanofi and Takeda have received approvals in the U.S., the EU and Japan for the Nuvaxovid formulation targeted at the SARS‑CoV‑2 variant XFG for the 2026–2027 vaccination season. The partners will handle distribution in their regions; Novavax will receive license fees and milestone payments tied to approvals without establishing its own sales infrastructure. Nuvaxovid is a protein-based vaccine using recombinant nanoparticle technology, is stored at 2–8 °C, and showed a good tolerability profile in a phase‑4 study. » Altro su de.investing.com


  • Novavax: option volume hits multi-month high, put options dominate

    Total Novavax option volume rose to 13,629 contracts by Friday. Call volume was 1,518 contracts (highest since April 18, 2024), put volume 12,111 contracts (highest since December 16, 2025). Two $8 puts dominated trading: 5,708 contracts expiring July 31, 2026 (open interest 91) and 5,675 contracts expiring July 17, 2026 (open interest 10,878). The stock fell 2.5% to $9.16. » Altro su de.investing.com

Nel 2012, Novavax ha già distribuito 9,39 € di dividendi. L'ultimo pagamento è avvenuto a marzo 2012.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Novavax ha registrato ricavi pari a 60,3 Mln € e un utile netto di -27,7 Mln €
(EUR) settembre 2026
YoY
Ricavi 60,3 Mln 0,45%
Utile lordo 39,56 Mln 5,16%
Utile netto -27,7 Mln 83,94%
EBITDA -18,72 Mln 88,50%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,28 Mld €
Numero di azioni
165,01 Mln
Massimo/minimo a 52 settimane
12,17 € - 5,63 €
Dividendi No
Beta
2,72
Rapporto P/E
-18,53
Rapporto PEG
0,29
Rapporto P/B
-6,48
Rapporto P/S
3,42

Profilo aziendale

Novavax, Inc., una società di biotecnologie, si occupa della scoperta, dello sviluppo e della commercializzazione di vaccini per prevenire gravi malattie infettive e rispondere a esigenze sanitarie. I candidati vaccini della società includono NVX-CoV2373, un candidato vaccino contro il coronavirus che si trova in due studi di Fase III, uno studio di Fase IIb e uno studio di Fase I/II; NanoFlu, un candidato vaccino nanoparticellare contro l'influenza stagionale quadrivalente che si trova in uno studio clinico di Fase 3; e ResVax, un candidato vaccino a nanoparticelle con proteina di fusione (F) del virus respiratorio sinciziale (RSV). L'azienda sta inoltre sviluppando un vaccino RSV F che si trova in uno studio clinico di Fase II per adulti anziani (60 anni e oltre), nonché in uno studio clinico di Fase I per la popolazione pediatrica. Ha un accordo di collaborazione con Takeda Pharmaceutical Company Limited per lo sviluppo, la produzione e la commercializzazione di NVX-CoV2373, un candidato vaccino contro la COVID-19. Novavax, Inc. è stata costituita nel 1987 e ha sede a Gaithersburg, nel Maryland.

Nome
Novavax
CEO
John Charles Jacobs
Sede centrale Gaithersburg, md
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
05/12/1995
Dipendenti 749

Simboli di borsa

Borsa Simbolo
NASDAQ
NVAX
XETRA
NVV1.F
Frankfurt
NVV1.F
Düsseldorf
NVV1.DU
Hamburg
NVV1.HM
London
0A3S.L
SIX
NVV1.SW
München
NVV1.MU
Wien
NVAX.VI
🍪

Parqet  usa i cookie. Scopri di più